Opioid Overdose and Mortality

The literature has consistently demonstrated a significantly increased 1-year mortality for patients who experience a nonfatal opioid overdose, with rates ranging from 4% to 15%. To put this in perspective, the estimated 1-year mortalities for uncomplicated type B aortic dissection and STEMI are 11-15% and 7-18% respectively.

A growing body of evidence strongly supports the mortality-reducing benefits of MOUD, particularly methadone and buprenorphine. Multiple studies across different populations and settings have demonstrated significant reductions in overdose mortality, all-cause mortality, and suicide risk when MOUD is initiated after a nonfatal opioid overdose or hospitalization.

MOUD Significantly Reduces All-Cause and Overdose Mortality

• Evans et al. (2015): A California cohort study found that individuals receiving MOUD had 50% lower all-cause mortality and 70% lower overdose mortality than those not receiving treatment.
• Sordo et al. (2017): A systematic review and meta-analysis reported that MOUD reduced all-cause mortality by 52% (SMR 0.48, 95% CI 0.41-0.57) and overdose mortality by 71% (SMR 0.29, 95% CI 0.20-0.41), with the most pronounced benefit in the first four weeks of treatment.
• Larochelle et al. (2018): A retrospective cohort study found that methadone and buprenorphine treatment after a nonfatal opioid overdose significantly reduced all-cause mortality (AHR 0.47 and 0.63, respectively) and opioid-related mortality (AHR 0.41 and 0.62, respectively).
• Babu et al. (2019): A review in NEJM found that methadone and buprenorphine reduced opioid-related mortality by 59% and 38%, respectively. ED-initiated buprenorphine increased treatment engagement and decreased long-term mortality.
• Weiner et al. (2024): A cohort study found that initiating MOUD within 7 days of an OUD-related ED visit reduced the odds of fatal or nonfatal overdose at 6 months (AOR 0.63, 95% CI 0.41-0.97), though this benefit was not sustained at 12 months, highlighting the need for continued treatment.

MOUD Reduces Suicide Risk

• Watts et al. (2022): A retrospective cohort study in VA patients found that MOUD reduced suicide mortality by 55% (AHR 0.45, 95% CI 0.32-0.63), along with reductions in external-cause and all-cause mortality.
• Nowels et al. (2024): A national Medicare study found that post-overdose MOUD was associated with an 80% reduction in suicide risk (AHR 0.20, 95% CI 0.05-0.85) in disability beneficiaries.
• Fraser et al. (2025): A national retrospective cohort study in Scotland found that opioid agonist therapy (OAT) was highly protective against suicide, with a 3.07-fold increased risk (95% CI 2.60-3.62) of suicide off OAT compared to on treatment.

ED-Initiated MOUD Improves Treatment Retention and Outcomes

• Bogan et al. (2020): A rural implementation study found that 76.6% of patients receiving ED-initiated buprenorphine attended a next-day follow-up appointment, and 59.9% remained in treatment at 30 days.
• Kimmel et al. (2020): A retrospective cohort study found that MOUD after hospitalization for injection drug use-associated infective endocarditis significantly reduced mortality in the month it was received (AHR 0.30, 95% CI 0.10-0.89).
• Morgan et al. (2020): A comparative effectiveness study found that outpatient MOUD was associated with the lowest 1-year overdose rate (2.2 per 100 person-years) and hospitalization rate (39 per 100 person-years) compared to inpatient treatments.
• Lowenstein et al. (2022): A multicomponent strategy to increase ED-initiated MOUD in three urban EDs resulted in a sustained 20% increase in buprenorphine use post-implementation. Despite variability in provider adoption, the strategy was associated with significant improvements in treatment engagement and process measures, highlighting the need for comprehensive approaches to enhance ED-based OUD care.
• Armour et al. (2024): A systematic review found that ED-initiated buprenorphine significantly increased treatment engagement at 30 days (OR 5.97, 95% CI 2.52-14.14) and had a low risk of precipitated withdrawal (0.00%, 95% CI 0.00-1.00%).

A nonfatal opioid overdose is a critical predictor of future mortality, with 1-year death rates comparable to major cardiovascular conditions. Evidence supports MOUD as a life-saving intervention, significantly reducing all-cause mortality, overdose-related deaths, and suicide risk. Furthermore, ED-initiated MOUD improves treatment engagement and long-term retention, underscoring the emergency department’s role as a pivotal starting point for intervention. Given the benefits and the high mortality risk, initiating MOUD in the ED should be considered a standard component of opioid overdose management.

1. Armour R, et al. Effectiveness of ED-initiated buprenorphine for opioid use disorder: A systematic review. JAMA Netw Open. 2024;7(3):e39577213. PubMed
2. Ashburn MA, et al. Mortality rates following nonfatal opioid overdose in North Carolina. Pain Med. 2020;21(7):1425-1433. PubMed
3. Babu KM, et al. The opioid epidemic: Crisis and solutions. N Engl J Med. 2019;380(23):2246-2255. NEJM
4. Bogan C, et al. Implementation of ED-initiated buprenorphine for opioid use disorder in rural settings. West J Emerg Med. 2020;21(2):137-144. PubMed
5. Bradley KA, et al. Mortality following naloxone administration by EMS in opioid overdose cases. Ann Emerg Med. 2018;72(5):629-636. PubMed
6. Evans E, et al. Comparative effectiveness of opioid use disorder treatment and overdose mortality. Am J Public Health. 2015;105(8):e60-e66. PMC
7. Fraser R, et al. Suicide risk among patients with opioid use disorder receiving opioid agonist therapy. Addiction. 2025;120(1):23-31. PubMed
8. Goldman-Mellor S, et al. Long-term mortality risk among opioid overdose survivors. Am J Epidemiol. 2020;189(5):463-472. PubMed
9. Kimmel SD, et al. MOUD and mortality outcomes in patients hospitalized for injection drug use-associated infections. Clin Infect Dis. 2020;72(3):e101-e109. PubMed
10. Larochelle MR, et al. Opioid agonist therapy after nonfatal opioid overdose and mortality outcomes. Ann Intern Med. 2018;169(3):137-145. PubMed
11. Leece P, et al. Opioid overdose and mortality outcomes in Ontario. JAMA Netw Open. 2019;2(8):e1910178. PubMed
12. Lowenstein M, et al. Enhancing ED-based opioid use disorder care: A multicomponent strategy. Ann Emerg Med. 2022;79(4):435-445. PubMed
13. Morgan JR, et al. Comparing outpatient and inpatient MOUD treatment outcomes. Drug Alcohol Depend. 2020;216:108346. PubMed
14. Nielsen S, et al. One-year mortality risk following nonfatal opioid overdose in Copenhagen. Addiction. 2011;106(8):1353-1360. PubMed
15. Nowels MA, et al. MOUD and suicide prevention in Medicare beneficiaries post-overdose. JAMA Psychiatry. 2024;81(2):133-142. PubMed
16. Olfson M, et al. National opioid overdose mortality trends and treatment engagement. Am J Psychiatry. 2019;176(10):908-916. PubMed
17. Sordo L, et al. Methadone and buprenorphine treatment effects on mortality: A systematic review and meta-analysis. BMJ. 2017;357:j1550. PubMed
18. Watts BV, et al. Suicide prevention and MOUD in U.S. Veterans Affairs patients. Psychiatry Res. 2022;307:114345. PubMed
19. Weiner SG, et al. MOUD initiation in the ED and overdose risk reduction. Ann Emerg Med. 2024;83(1):65-74. PubMed